Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia

Measurable residual disease (MRD) is a powerful predictor of outcome in acute myeloid leukemia (AML). In the early phases of treatment, MRD refines initial disease risk stratification and is used for the allocation to allogeneic transplant (HSCT). Despite its well-established role, a relatively high fraction of patients eventually relapses albeit achieving MRDneg status. The aim of this work was to assess specifically the influence of baseline features and treatment intensity on the predictive value of an MRDneg status, particularly focusing on MRD2, measured after 2 consecutive chemotherapeutic cycles. Among baseline features, younger MRD2neg patients (.